Abstract 15580: Cerebral Microbleeds Are Associated With High Systolic Arterial Blood Pressure, but Not Arterial Stiffness in Patients With Cardiovascular Disease
Background: Gradient-echo T2*-weighted magnetic resonance imaging (MRI) is highly sensitive for detecting cerebral microbleeds (CMBs). The presence of CMBs is thought to correlate with anticoagulant therapy and is a marker of future cerebral hemorrhage and cardiovascular mortality. We investigated the possible association of CMBs with systolic blood pressure (BPs) level and arterial stiffness in patients with cardiovascular disease.
Methods: In total, we enrolled 278 patients with cardiovascular disease (mean age: 70 ± 11 years, 193 males), who underwent brain MRI as well as systemic screening for premature atherosclerosis, including ankle brachial index, brachial-ankle pulse wave velocity examination (baPWV), and carotid ultrasonography for the measurement of intima-media thickness (IMT). CMBs were coded by researchers blind to clinical details. Based on their mean BPs level, patients were categorized into groups having very low-normal (<110 mm Hg), low-normal (110-130 mmHg), moderately high (130-150 mmHg), and very high BPs (>150 mm Hg).
Results: CMBs were observed in 90 patients (32%) and were most frequently seen in the basal ganglia (65%), followed by the cerebral cortex (23%). The BPs and baPWV were significantly higher in patients with CMBs than in those without (BPs, 131 ± 21 vs 137 ± 20 mmHg, P = 0.020 ; baPWV; 1636 ± 410 vs 1725 ± 415 cm/s, P = 0.048). The carotid IMT did not differ significantly between patients with CMBs and those without (max IMT, 1.17 ± 0.5 vs 1.20 ± 0.4 mm, P = 0.68; mean IMT, 0.93 ± 0.3 vs 0.95 ± 0.3 mm, P = 0.48). After adjustment for potential confounding variables, such as antithrombotic drug use, CMBs were found to be more prevalent among patients with the very high BPs than among those with low-normal BPs (odds ratio 3.27, 95% CI 1.11-10.4; P = 0.008).
Conclusions: CMBs were associated with high BPs (BPs > 150 mmHg) in patients with cardiovascular disease, but not with arterial stiffness or antithrombotic drug use.
Author Disclosures: Y. Yamauchi: None. Y. Kanzaki: None. Y. Wada: None. H. Shima: None. N. Ishizaka: None.
- © 2016 by American Heart Association, Inc.